Agilent Technologies and Seoul National University hospital collaborate on biomarker research
Goals include development, verification of biomarkers for use in drug development
SANTA CLARA, Calif., and SEOUL, Korea -- Agilent Technologies Inc. (NYSE: A) and Seoul National University Hospital, one of Korea's top medical centers, today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
'There are gaps in the medical industry that hamper the quality of care we can provide to patients,' said Prof. Byung-Hee Oh, president and CEO, Seoul National University Hospital. 'One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases.'
'Our hospital is pleased to collaborate with Agilent, the premier test and measurement company, to help us stretch the horizons of medical research in order to improve the lives of people in Korea and around the world,' he said.
Under the agreement, the hospital's Department of Laboratory Medicine will use the Agilent 6460 Triple Quadrupole LC/MS system as well as Agilent's support services and application expertise. The hospital is committed to creating and maintaining an optimal environment for new biomarkers to be identified and tested rigorously by highly sensitive yet robust instruments.
'We are privileged to partner with Seoul National University Hospital, which has a strong tradition of innovation and quality care for customers,' said Agilent's Rod Minett, general manager, Life Sciences, South Korea and the South Asia-Pacific region. 'Through this collaboration, we hope to establish more effective and varied verifications system for the medical and life sciences industries.'
About Seoul National University Hospital
Seoul National University Hospital has been looking after public health over the past 100 years, leading the development of medicine in Korea. It was established in 1885 as Korea's first national hospital under the name of Kwang Hye Won. It became the affiliate hospital for Seoul National University's College of Medicine and College of Dentistry before being recognized as a special corporate body under the name of Seoul National University Hospital. Today, the hospital is comprised of the Main Hospital, the Children's Hospital, the Caner Hospital, the Dental Hospital, and the Clinical Research Institute. For more information, please visit www.snuh.org/english.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had net revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
Related news
-
CD Genomics Fully Supports Your Microbiome Research with Comprehensive Sequencing Solutions
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance of human and animal microbiota. Through long-term and detailed studies of the gut microbiota, scientists have revealed the complex relationship...
-
Creative Proteomics's Targeted Metabolomic Platform Supports Ketone Body Detection
Creative Proteomics is an experienced outsourcing service provider offering professional and high-quality multi-omics services to academic research institutions and pharmaceutical industry. Creative Proteomics offers targeted metabolomics services for the enrichment and accurate quantitative profiling of a specific metabolite in blood, urine or other body fluids and tissues under specific physiological or pathological conditions. Targeted metabolomics is a qualitative and quantitative analysis method for...
-
CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Whole Transcriptome Sequencing to its offerings. Now scientists and researchers worldwide can easily obtain whole transcriptome sequencing needed in their...
-
SARS-CoV-2 Glycosylation Profiling Service Now Available at CD BioGlyco
CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic. The US FDA has approved Pfizer and Moderna`s two vaccines for sale in the US market. The scientific community is still trying to understand the virus in many...
-
Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis
Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease (AD). Blood Test Will be...
Customer comments
No comments were found for Agilent Technologies and Seoul National University hospital collaborate on biomarker research. Be the first to comment!